

### REMARKS

The specification has been amended to recite the information regarding the parent application, priority benefits of which are claimed under 35 U.S.C. § 120 and to correct typographical errors in the application as originally filed. According to the amino acid sequence of the wild-type penicillin expandase listed as SEQ ID NO: 1 in the specification as filed, the 79<sup>th</sup> amino acid of the wild-type expandase is glycine (G) instead of serine (S).

Claims 1-3 and 11-14 have been cancelled without prejudice as directed to a separate invention as indicated by the restriction requirement received in connection with the parent application. Originally dependent claim 4 has been amended to read as an independent claim by reciting the subject matter of claim 1. Accordingly, claims 4-10 will be pending upon entry of the present amendments.


The above-made amendments are fully supported by the original application, especially the sequence listing as filed. No new matter has been introduced.

Entry of the amendments into the file is respectfully requested. It is also respectfully requested that all the listed references be reviewed and made of record in the present application.

It is estimated that no fee is required for filing this Preliminary Amendment. In the event a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: November 21, 2003

  
Geraldine F. Baldwin 31,232  
(Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090